

19. Wollner A, Mohle-Boetani J, Lambert ER, Perruquet JL, Thomas A. *Pneumocystis carinii* pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. *Thorax*. 1991;46:205–7. <http://dx.doi.org/10.1136/thx.46.3.205>
20. Health Protection Agency. United Kingdom new HIV diagnoses to end of June 2011 [cited 2012 Feb 2]. [http://www.hpa.org.uk/webc/HPAwebFile/HPAweb\\_C/1237970242135](http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1237970242135)
21. StataCorp. Stata Statistical Software: release 11. College Station, TX: StataCorp LP; 2009.
22. Gallant JE, McAvinue SM, Moore RD, Bartlett JG, Stanton DL, Chaisson RE. The impact of prophylaxis on outcome and resource utilization in *Pneumocystis carinii* pneumonia. *Chest*. 1995;107:1018–23. <http://dx.doi.org/10.1378/chest.107.4.1018>
23. Leigh TR, Gazzard B, Rowbottom A, Collins J. Quantitative and qualitative comparison of DNA amplification by PCR with immunofluorescence staining for diagnosis of *Pneumocystis carinii* pneumonia. *J Clin Pathol*. 1993;46:140–4. <http://dx.doi.org/10.1136/jcp.46.2.140>
24. Office for National Statistics. Cancer statistics registrations, England (Series MB1) No. 41, 2010 [cited 2011 Aug 26]. [http://www.ons.gov.uk/ons/dcp171778\\_267154.pdf](http://www.ons.gov.uk/ons/dcp171778_267154.pdf)
25. European Best Practices Guidelines Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.7.1 Late infections. *Pneumocystis carinii* pneumonia. *Nephrol Dial Transplant*. 2002;17:36–9. [http://dx.doi.org/10.1093/ndt/17.suppl\\_4.36-a](http://dx.doi.org/10.1093/ndt/17.suppl_4.36-a)
26. Kidney Disease; Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*. 2009;9(Suppl 3):S1–155. <http://dx.doi.org/10.1111/j.1600-6143.2009.02834.x>
27. Worth LJ, Dooley MJ, Seymour JF, Mileskin L, Slavin MA, Thursky KA. An analysis of the utilization of chemoprophylaxis against *Pneumocystis jirovecii* pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. *Br J Cancer*. 2005;92:867–72. <http://dx.doi.org/10.1038/sj.bjc.6602412>
28. Central South Coast Cancer Network. Guidelines for the management of haematological malignancies March 2010. [cited 2011 Aug 26]. <http://www.cscn.nhs.uk/uploads/networkgrp/20101102104803-Network-Haematological-Malignancy-Guidelines-2010.pdf>
29. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for *Pneumocystis* pneumonia (PCP) in non-HIV immunocompromised patients (review) [cited 2013 Jan 7]. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005590.pub2/pdf/standard>
30. Wynckel A, Toubas D, Noël N, Toupance O, Rieu P. Outbreak of *Pneumocystis* pneumonia occurring in late post-transplantation period. *Nephrol Dial Transplant*. 2011;26:2417. <http://dx.doi.org/10.1093/ndt/gfr159>
31. Phipps LM, Chen SC, Kable K, Halliday CL, Firacative C, Meyer W, et al. Nosocomial *Pneumocystis jirovecii* pneumonia: lessons from a cluster in kidney transplant recipients. *Transplantation*. 2011;92:1327–34. <http://dx.doi.org/10.1097/TP.0b013e3182384b57>
32. de Boer MG, de Fijter JW, Kroon FP. Outbreaks and clustering of *Pneumocystis* pneumonia in kidney transplant recipients: a systematic review. *Med Mycol*. 2011;49:673–80.

Address for correspondence: Katherine L. Henderson, Health Protection Agency, 61 Colindale Ave, London, NW9 5EQ, UK; email: Katherine.Henderson@hpa.org.uk

# etymologia

## *Leptospira* [lep'to-spi'rə]

From the Greek *leptos* (slender) and *speira* (coil), a genus of bacteria consisting of single, finely coiled, motile, aerobic cells. In 1886, German physician Adolf Weil described a clinical syndrome characterized by splenomegaly, jaundice, and nephritis, although the disease was likely recognized in ancient China as an occupational hazard of rice farming. The organism was first described in 1907 by Arthur Stimson, who observed spirochetes with curved ends in the kidneys of a patient thought to have died of yellow fever. He named it *Spirochaeta interrogans* because it looked like a question mark.

### Sources

1. Dorland's Illustrated Medical Dictionary. 32nd ed. Philadelphia: Elsevier Saunders; 2012.
2. Inada R, Ido Y, Hoki R, Kaneko R, Ito H. The etiology, mode of infection, and specific therapy of Weil's disease (spirochaetosis icterohaemorrhagica). *J Exp Med*. 1916;23:377–402. <http://dx.doi.org/10.1084/jem.23.3.377>
3. Levett PN. Leptospirosis. *Clin Microbiol Rev*. 2001;14:296–326. <http://dx.doi.org/10.1128/CMR.14.2.296-326.2001>
4. Noguchi H. *Spirochaeta icterohaemorrhagiae* in American wild rats and its relation to the Japanese and European strains. *J Exp Med*. 1917;25:755–63. <http://dx.doi.org/10.1084/jem.25.5.755>
5. Vijayachari P, Sugunan AP, Shriram AN. Leptospirosis: an emerging global public health problem. *J Biosci*. 2008;33:557–69. <http://dx.doi.org/10.1007/s12038-008-0074-z>

Address for correspondence: Ronnie Henry, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03, Atlanta, GA 30333, USA; email: boq3@cdc.gov

DOI: <http://dx.doi.org/10.3201/eid1903.AD1903>